GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (OSTO:VICO BTA) » Definitions » Cyclically Adjusted PB Ratio

Vicore Pharma Holding AB (OSTO:VICO BTA) Cyclically Adjusted PB Ratio : (As of Jul. 14, 2025)


View and export this data going back to . Start your Free Trial

What is Vicore Pharma Holding AB Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vicore Pharma Holding AB Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicore Pharma Holding AB Cyclically Adjusted PB Ratio Chart

Vicore Pharma Holding AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 1.36

Vicore Pharma Holding AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 3.34 1.16 1.36 1.14

Competitive Comparison of Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio falls into.


;
;

Vicore Pharma Holding AB Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Vicore Pharma Holding AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Vicore Pharma Holding AB's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=89.74/132.8245*132.8245
=89.740

Current CPI (Mar. 2025) = 132.8245.

Vicore Pharma Holding AB Quarterly Data

Book Value per Share CPI Adj_Book
201506 5.411 99.995 7.188
201509 0.000 100.228 0.000
201512 7.206 100.276 9.545
201603 7.066 100.751 9.315
201606 6.947 101.019 9.134
201609 6.808 101.138 8.941
201612 2.778 102.022 3.617
201703 8.965 102.022 11.672
201706 10.664 102.752 13.785
201709 10.516 103.279 13.524
201712 5.064 103.793 6.480
201803 10.311 103.962 13.174
201806 10.761 104.875 13.629
201809 12.721 105.679 15.989
201812 25.107 105.912 31.487
201903 24.606 105.886 30.866
201906 22.316 106.742 27.769
201909 20.341 107.214 25.200
201912 28.287 107.766 34.865
202003 26.059 106.563 32.481
202006 23.989 107.498 29.641
202009 36.238 107.635 44.719
202012 31.182 108.296 38.245
202103 55.339 108.360 67.833
202106 49.186 108.928 59.977
202109 40.689 110.338 48.981
202112 33.716 112.486 39.812
202203 25.615 114.825 29.630
202206 20.061 118.384 22.508
202209 14.135 122.296 15.352
202212 25.427 126.365 26.727
202303 19.755 127.042 20.654
202306 26.573 129.407 27.275
202309 49.828 130.224 50.823
202312 40.055 131.912 40.332
202403 42.997 132.205 43.198
202406 38.260 132.716 38.291
202409 33.225 132.304 33.356
202412 99.334 132.987 99.212
202503 89.740 132.825 89.740

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vicore Pharma Holding AB  (OSTO:VICO BTA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Vicore Pharma Holding AB Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vicore Pharma Holding AB Business Description

Traded in Other Exchanges
Address
Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2b development for IPF. The company also has an investigational medical device in clinical development, namely, Almee, which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines